Overall, our study provides insight into the mechanism of action of drugs targeting the CXCL12/CXCR4 axis, the IL6/IL6R axis, or other SASP protein signaling pathways in MM, and suggests that targeting proteins identified herein may lead to new therapeutic avenues. This evidence concerns the gene CXCR4 and Miyoshi myopathy.